Pinpoint’s Advanced Disposable Plasmonic Assay (DPA) Biosensors are engineered for high-precision, multi-pathogen detection, capable of identifying multiple infectious agents from a single sample. Designed for cost-effective, high-throughput diagnostics, they offer a scalable solution for the consumable biosensor market—delivering real-time pathogen monitoring with exceptional efficiency and affordability.
Why It Matters
The global hospital-acquired infection (HAI) control market was valued at $29.1 billion in 2021, while the air filtration and sterilisation market stood at $12.26 billion. Both sectors continue to grow as public health and infection control take centre stage globally.
The COVID-19 pandemic has created an urgent, lasting demand for rapid, reliable pathogen monitoring across public spaces—hospitals, schools, transit systems, commercial buildings, and event venues. Pinpoint’s DPA technology enables simultaneous detection of multiple airborne or surface pathogens, with a clear market edge: fast, simple operation at a lower cost than traditional methods.
Competing systems—such as optical, label-free biosensors like surface plasmon resonance (Cytiva, HORIBA, Nicoya, Fox Biosystems) or bilayer interferometry (Sartorius)—lack the field-readiness, single-step diagnostics, and full multiplexing capability of the Pinpoint solution. Our biosensors are designed for real-world deployment, not just the lab.
PinPoint Medical has identified a critical gap in the biosensor market, presenting a unique opportunity for disruptive innovation. Existing biosensing technologies are often cost-prohibitive and suffer from long turnaround times, limiting their efficacy in real-time pathogen detection and disease prevention.
PinPoint Medical has identified a critical gap in the biosensor market, presenting a unique opportunity for disruptive innovation. Existing biosensing technologies are often cost-prohibitive and suffer from long turnaround times, limiting their efficacy in real-time pathogen detection and disease prevention.
Next-Generation Biosensors: Rapid, Multi- Pathogen Detection at a Lower Cost –
Closing a Critical Gap in Biosensing
At Pinpoint Medical, we’ve identified a fundamental shortfall in the current biosensor landscape—one that presents a clear opportunity for disruptive innovation.
Most existing biosensing technologies are either too costly or too slow to support real-time pathogen detection at scale. Long turnaround times and complex workflows make them impractical for frontline disease prevention, especially in high-risk environments where speed and simplicity are essential.
Pinpoint’s solution fills that gap—delivering fast, affordable, and scalable diagnostics without compromising on precision or performance.
Our Advanced Disposable Plasmonic Assay (DPA) biosensors are designed to deliver rapid, high-precision pathogen detection at a significantly lower cost than traditional solutions. Unlike conventional immunosensors such as lateral flow devices, our high-throughput technology minimises reagent usage, reducing operational costs while maintaining high sensitivity and reliability.
Originally developed for integration with our Pinpoint Intelligent Air Quality (iAQ) Filtration System, this biosensor technology enables real-time, point-of-contact monitoring of airborne pathogens in critical environments, including hospitals, transport hubs, schools, and laboratories.
In addition to environmental monitoring, we are actively developing white-label solutions, allowing third-party healthcare, biotech, and diagnostics companies to integrate our sensors into their own biosensing applications—greatly expanding market potential.
While DPA biosensors can be seamlessly integrated into existing third-party systems, Pinpoint Medical is also building a fully integrated diagnostic ecosystem, including a wireless biosensor reader and an advanced software platform for sensor calibration, data capture, and real-time reporting. This end-to-end solution will enable instant pathogen detection and generate automated alerts for airborne contamination risks—ensuring rapid response and infection control.
At the concept stage, we are developing a continuous real-time monitoring solution that integrates sensor and reader technology to provide automated early-warning detection of pathogen accumulation in high-risk settings such as operating theatres, cleanrooms, and laboratory facilities. This innovation has the potential to redefine biosecurity protocols, supporting proactive disease mitigation in critical healthcare and research environments.
Our Advanced Disposable Plasmonic Assay (DPA) biosensors are designed to deliver rapid, high-precision pathogen detection at a significantly lower cost than traditional solutions. Unlike conventional immunosensors such as lateral flow devices, our high-throughput technology minimises reagent usage, reducing operational costs while maintaining high sensitivity and reliability.
Originally developed for integration with our Pinpoint Intelligent Air Quality (iAQ) Filtration System, this biosensor technology enables real-time, point-of-contact monitoring of airborne pathogens in critical environments, including hospitals, transport hubs, schools, and laboratories.
In addition to environmental monitoring, we are actively developing white-label solutions, allowing third-party healthcare, biotech, and diagnostics companies to integrate our sensors into their own biosensing applications—greatly expanding market potential.
While DPA biosensors can be seamlessly integrated into existing third-party systems, Pinpoint Medical is also building a fully integrated diagnostic ecosystem, including a wireless biosensor reader and an advanced software platform for sensor calibration, data capture, and real-time reporting. This end-to-end solution will enable instant pathogen detection and generate automated alerts for airborne contamination risks—ensuring rapid response and infection control.
At the concept stage, we are developing a continuous real-time monitoring solution that integrates sensor and reader technology to provide automated early-warning detection of pathogen accumulation in high-risk settings such as operating theatres, cleanrooms, and laboratory facilities. This innovation has the potential to redefine biosecurity protocols, supporting proactive disease mitigation in critical healthcare and research environments.
Our Advanced Disposable Plasmonic Assay (DPA) biosensors are designed to deliver rapid, high-precision pathogen detection at a significantly lower cost than traditional solutions. Unlike conventional immunosensors such as lateral flow devices, our high-throughput technology minimises reagent usage, reducing operational costs while maintaining high sensitivity and reliability.
Originally developed for integration with our Pinpoint Intelligent Air Quality (iAQ) Filtration System, this biosensor technology enables real-time, point-of-contact monitoring of airborne pathogens in critical environments, including hospitals, transport hubs, schools, and laboratories.
In addition to environmental monitoring, we are actively developing white-label solutions, allowing third-party healthcare, biotech, and diagnostics companies to integrate our sensors into their own biosensing applications—greatly expanding market potential.
While DPA biosensors can be seamlessly integrated into existing third-party systems, Pinpoint Medical is also building a fully integrated diagnostic ecosystem, including a wireless biosensor reader and an advanced software platform for sensor calibration, data capture, and real-time reporting. This end-to-end solution will enable instant pathogen detection and generate automated alerts for airborne contamination risks—ensuring rapid response and infection control.
At the concept stage, we are developing a continuous real-time monitoring solution that integrates sensor and reader technology to provide automated early-warning detection of pathogen accumulation in high-risk settings such as operating theatres, cleanrooms, and laboratory facilities. This innovation has the potential to redefine biosecurity protocols, supporting proactive disease mitigation in critical healthcare and research environments.
Real Time Pathogen Monitoring for a safer, Healthier Future
At Pinpoint Medical, our commitment to innovation is rooted in a clear mission: to transform how the world detects, monitors, and responds to infectious threats. Our Disposable Plasmonic Assay (DPA) biosensors represent a step-change in real-time pathogen detection—combining high precision with cost-efficiency to address urgent challenges in both healthcare and environmental safety.
As we advance and scale our technology, our focus remains on delivering powerful tools that improve infection control, elevate air quality standards, and support proactive disease prevention across high-risk settings.
This is a pivotal moment for biosensing innovation, and we’re proud to be at the forefront—driving the next generation of diagnostic solutions that will shape the future of global health security.
At Pinpoint Medical, our commitment to innovation is rooted in a clear mission: to transform how the world detects, monitors, and responds to infectious threats. Our Disposable Plasmonic Assay (DPA) biosensors represent a step-change in real-time pathogen detection—combining high precision with cost-efficiency to address urgent challenges in both healthcare and environmental safety.
As we advance and scale our technology, our focus remains on delivering powerful tools that improve infection control, elevate air quality standards, and support proactive disease prevention across high-risk settings.
This is a pivotal moment for biosensing innovation, and we’re proud to be at the forefront—driving the next generation of diagnostic solutions that will shape the future of global health security.
Phone: +44 (0)7796 777 739
Email: info@pinpointmedical.co.uk
Address: St Colmes, Ballinluig, Pitlochry, United Kingdom, PH9 0NR
Phone: +44 (0)7796 777 739
Email: info@pinpointmedical.co.uk